HomeDMN • FRA
add
Diamyd Medical AB
Previous close
€1.45
Day range
€1.46 - €1.46
Year range
€0.65 - €1.78
Market cap
1.76B SEK
Avg Volume
2.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Nov 2024info | Y/Y change |
|---|---|---|
Revenue | 25.00K | -26.47% |
Operating expense | 41.86M | 40.27% |
Net income | -36.16M | -10.31% |
Net profit margin | -144.65K | -50.02% |
Earnings per share | — | — |
EBITDA | -41.40M | -39.63% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Nov 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 152.88M | -13.49% |
Total assets | 222.89M | -15.45% |
Total liabilities | 66.78M | 25.66% |
Total equity | 156.11M | — |
Shares outstanding | 104.09M | — |
Price to book | 0.97 | — |
Return on assets | -48.78% | — |
Return on capital | -71.05% | — |
Cash Flow
Net change in cash
| (SEK) | Nov 2024info | Y/Y change |
|---|---|---|
Net income | -36.16M | -10.31% |
Cash from operations | -41.82M | -50.37% |
Cash from investing | 24.06M | 820.26% |
Cash from financing | 59.07M | -27.87% |
Net change in cash | 40.12M | -18.43% |
Free cash flow | -31.11M | -43.94% |
About
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. Wikipedia
Founded
1984
Website
Employees
29
